154 related articles for article (PubMed ID: 14743459)
21. PSA relapse prostate cancer: the importance of tailored therapy.
Aranha O; Vaishampayan U
Urol Oncol; 2004; 22(1):62-9. PubMed ID: 14969807
[TBL] [Abstract][Full Text] [Related]
22. Incidence of urethral stricture after primary treatment for prostate cancer: data From CaPSURE.
Elliott SP; Meng MV; Elkin EP; McAninch JW; Duchane J; Carroll PR;
J Urol; 2007 Aug; 178(2):529-34; discussion 534. PubMed ID: 17570425
[TBL] [Abstract][Full Text] [Related]
23. The impact of prior radical prostatectomy in men with metastatic castration recurrent prostate cancer: a pooled analysis of 9 Cancer and Leukemia Group B Trials.
Halabi S; Vogelzang NJ; Ou SS; Small EJ
J Urol; 2007 Feb; 177(2):531-4. PubMed ID: 17222627
[TBL] [Abstract][Full Text] [Related]
24. [New aspects in prostate cancer therapy].
Dvorácek J
Cas Lek Cesk; 2007; 146(10):736-45. PubMed ID: 18020004
[TBL] [Abstract][Full Text] [Related]
25. A retrospective study of the treatment of locally advanced prostate cancer by six institutions in eastern and north-eastern Japan.
Hachiya T; Akakura K; Saito S; Shinohara N; Sato K; Harada M; Kato T; Okada K
BJU Int; 2005 Mar; 95(4):534-40. PubMed ID: 15705075
[TBL] [Abstract][Full Text] [Related]
26. [Radiotherapy combined with hormonal therapy as treatment method in patients with prostate cancer: still more questions than answers].
Milecki P
Przegl Lek; 2005; 62(12):1455-9. PubMed ID: 16786772
[TBL] [Abstract][Full Text] [Related]
27. Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer.
Galalae RM; Martinez A; Mate T; Mitchell C; Edmundson G; Nuernberg N; Eulau S; Gustafson G; Gribble M; Kovács G
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1048-55. PubMed ID: 15001244
[TBL] [Abstract][Full Text] [Related]
28. [Practice guideline 'Prostate cancer: diagnosis and treatment'].
de Reijke TM; Battermann JJ; van Moorselaar RJ; de Jong IJ; Visser AP; Burgers JS
Ned Tijdschr Geneeskd; 2008 Aug; 152(32):1771-5. PubMed ID: 18754308
[TBL] [Abstract][Full Text] [Related]
29. Intermediate-risk localized prostate cancer in the PSA era: radiotherapeutic alternatives.
Gondi V; Deutsch I; Mansukhani M; O'Toole KM; Shah JN; Schiff PB; Katz AE; Benson MC; Goluboff ET; Ennis RD
Urology; 2007 Mar; 69(3):541-6. PubMed ID: 17382161
[TBL] [Abstract][Full Text] [Related]
30. Quality of life for men with prostate cancer.
Katz A
Cancer Nurs; 2007; 30(4):302-8. PubMed ID: 17666980
[TBL] [Abstract][Full Text] [Related]
31. A randomized trial comparing radical prostatectomy plus endocrine therapy versus external beam radiotherapy plus endocrine therapy for locally advanced prostate cancer: results at median follow-up of 102 months.
Akakura K; Suzuki H; Ichikawa T; Fujimoto H; Maeda O; Usami M; Hirano D; Takimoto Y; Kamoto T; Ogawa O; Sumiyoshi Y; Shimazaki J; Kakizoe T;
Jpn J Clin Oncol; 2006 Dec; 36(12):789-93. PubMed ID: 17082219
[TBL] [Abstract][Full Text] [Related]
32. Predictors of overall and cancer-free survival of patients with localized prostate cancer treated with primary androgen suppression therapy: results from the prostate cancer outcomes study.
Graff JN; Mori M; Li H; Garzotto M; Penson D; Potosky AL; Beer TM
J Urol; 2007 Apr; 177(4):1307-12. PubMed ID: 17382720
[TBL] [Abstract][Full Text] [Related]
33. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data.
Teh BS; Ayala G; Aguilar L; Mai WY; Timme TL; Vlachaki MT; Miles B; Kadmon D; Wheeler T; Caillouet J; Davis M; Carpenter LS; Lu HH; Chiu JK; Woo SY; Thompson T; Aguilar-Cordova E; Butler EB
Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1520-9. PubMed ID: 15050332
[TBL] [Abstract][Full Text] [Related]
34. Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study.
Potosky AL; Davis WW; Hoffman RM; Stanford JL; Stephenson RA; Penson DF; Harlan LC
J Natl Cancer Inst; 2004 Sep; 96(18):1358-67. PubMed ID: 15367568
[TBL] [Abstract][Full Text] [Related]
35. Prostate cancer update: 2007.
Lin AM; Small EJ
Curr Opin Oncol; 2008 May; 20(3):294-9. PubMed ID: 18391629
[TBL] [Abstract][Full Text] [Related]
36. Prostate specific antigen recurrence after definitive therapy.
Freedland SJ; Moul JW
J Urol; 2007 Jun; 177(6):1985-91. PubMed ID: 17509277
[TBL] [Abstract][Full Text] [Related]
37. The National Prostate Cancer Register in Sweden 1998-2002: trends in incidence, treatment and survival.
Varenhorst E; Garmo H; Holmberg L; Adolfsson J; Damber JE; Hellström M; Hugosson J; Lundgren R; Stattin P; Törnblom M; Johansson JE
Scand J Urol Nephrol; 2005; 39(2):117-23. PubMed ID: 16019764
[TBL] [Abstract][Full Text] [Related]
38. Contemporary use of hormonal therapy in prostate cancer: managing complications and addressing quality-of-life issues.
Gomella LG
BJU Int; 2007 Jan; 99 Suppl 1():25-9; discussion 30. PubMed ID: 17229166
[TBL] [Abstract][Full Text] [Related]
39. Pretreatment prostate-specific antigen velocity is associated with development of distant metastases and prostate cancer mortality in men treated with radiotherapy and androgen-deprivation therapy.
Palma D; Tyldesley S; Pickles T;
Cancer; 2008 May; 112(9):1941-8. PubMed ID: 18338814
[TBL] [Abstract][Full Text] [Related]
40. Timing of androgen deprivation therapy and its impact on survival after radical prostatectomy: a matched cohort study.
Siddiqui SA; Boorjian SA; Inman B; Bagniewski S; Bergstralh EJ; Blute ML
J Urol; 2008 May; 179(5):1830-7; discussion 1837. PubMed ID: 18353378
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
